At its meeting on 24 June 2024, the Transparency Council adopted opinion No. 100/2024 on the inclusion in the reimbursement of medicines containing the active substance propranolol in terms of indications for use or dosage, or method of administration different from those specified in the Summary of Product Characteristics. of Medicinal Product.
Publication on the list of opinions on active substances for off-label indications >>